表柔比星联合环磷酰胺治疗乳腺癌改良根治术后患者的疗效分析

Clinical Efficacy of Epirubicin Combined with Cyclophosphamide for treatment of the Patients with Breast Cancer after Modified Radical Surgery

目的研究乳腺癌改良根治术后应用表柔比星与环磷酰胺联合化疗方案对患者的疗效及生存率的影响。方法选取2013年2月~2014年4月于我院接受乳腺癌改良根治术的乳腺癌患者86例。根据随机数字表法分为观察组及对照组,每组各43例。对照组采用多西他赛与表柔比星联合化疗方案治疗,观察组应用表柔比星与环磷酰胺联合化疗方案治疗。分别比较两组临床疗效、各项手术指标水平、不良反应发生率以及1~3年生存率。结果观察组治疗总有效率为95.35%,显著高于对照组(67.44%)(P<0.05)。观察组患者住院时间为(3.3±0.5)d,对照组为(7.1±1.4)d,差异无统计学意义(P<0.05)。观察组中性粒细胞减少、恶心呕吐的发生率分别为74.42%、51.16%,显著低于对照组(100.00%,79.07%)(P<0.05)。观察组3年生存率为86.05%,与对照组(67.44%)比较,差异有统计学意义(P<0.05)。结论乳腺癌改良根治术后应用表柔比星与环磷酰胺联合化疗的疗效较好,可有效提高治疗安全性及生存率。

Objective To study the effect of epirubicin and cyclophosphamide combination chemotherapy on the efficacy and survival rate for breast cancer patients after modified radical mastectomy Methods 86 patients with breast cancer were treated by modified radi-cal mastectomy for breast cancer patients from February 2013 to April 2014 in our hospital. They were randomly divided into observation group and control group, 43 cases in each group. The patients in control group were treated with docetaxel combined with epirubicin, and the patients in observation group application of epirubicin and cyclophosphamide combination respectively. The clinical efficacy, the index of operation level, the incidence of adverse reaction of the two groups between 1 and 3 years survival rate were analyzed. Results The total effective rate of patients in observation group was 95.35%, significantly higher than that in control group （67.44%） （P〈0.05）. The hospitali-zation time of patients in the observation group was （3.3±0.5） d, there was no significant difference compared with that in the control group [ （7.1±1.4） d] （P〈0.05）. The occurrence rates of neutropenia, nausea and vomiting in observation groups were 74.42%, 51.16%, which were significantly decreased compared with those in the control group （100.00%, 79.07%） （P〈0.05）. The observation group 3-year survival rate was 86.05%, and in the control group was 67.44%, the difference was statistically significant （P〈0.05）. Conclusion The application of epirubicin in modified radical mastectomy is better for patients with breast cancer, and it can improve the safety and survival rate of patients.